Sitagliptin for Prevention of aGVHD After Alternative Donor Transplatation
-
- STATUS
- Recruiting
-
- End date
- Dec 24, 2023
-
- participants needed
- 190
-
- sponsor
- The First Affiliated Hospital of Soochow University
Summary
Primary Objective:
It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related haploid or unrelated donor ) allogeneic hematopoietic stem cell transplantation and receiving standard GVHD prophylaxis.
Secondary Objectives
The following descriptive secondary objectives will be studied:
- Determine the tolerability and potential toxicity of sitagliptin in patients undergoing allogeneic HSCT.
- Determine the cumulative incidence of grades II-IV acute GVHD by day +100.
- To investigate the cumulative incidence of grades III-IV acute GVHD.
- To investigate the engraftment kinetics of absolute neutrophil count and platelets.
- To evaluate the incidence of CMV, EBV and other infections occurring during the 100 days post-transplant.
- To study non-relapse mortality (NRM) at day +100, and 1 year post-transplant.
- Determine the overall survival at 1 year post-transplant.
- Determine the incidence of chronic GVHD.
- Determine the cumulative incidence of relapse of the primary hematological malignancy.
Description
This is a Prospective, Multi-center, Open-label, Randomized, Controlled clinical trial of Sitagliptin for the prevention and safety of aGVHD after Alternative Donor hematopoietic stem cell transplantation.
190 adult patients with hematologic malignancies receiving haploid or unrelated donor sourced HSCT are planned to be enrolled competitively in this study from 5 clinical centers in China. These patients will be randomly assigned to two groups of 95 patients each, which one is experimental group and the other is control group. 95 patients in experimental group will receive Sitagliptin combined with Standard prophylaxis for GVHD. 95 patients in the control group will receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
Control group uses ATG+CSA+MMF+MTX for GVHD prophylaxis with the details as follows: CSA 3mg/kg continuous i.v. drip, start before Day -7, change to p.o. when gastrointestinal function recovers with a dose of 5mg/kg as two divided doses, maintaining CSA within 150-250ng/ml（If CsA cannot be tolerated, tacrolimus may be used as an alternative.）; MTX 15mg/m2,Day +1, 10mg/m2,Days +3, +6, and +11; MMF 0.5g BID, starting from Day -7 to day +30 for one month; ATG 2.5mg/kg/d, Day -4 to Day -1.
Experimental group will take Sitagliptin orally from d-1 to d+14 in addition to Standard Prophylaxis Regimen.
With regard to the content of dose reduction of CSA (including time and reduction rate), it is recommended for patients with hematologic malignancies in standard risk group to start to reduce dose after 3-6 months in the absence of GVHD and reoccurance. The specific reduction rate can be determined at each site; the patients with GVHD will be managed by routine practice in this site.
Details
| Condition | Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation |
|---|---|
| Treatment | Sitagliptin + Standard Prophylaxis, Standard Prophylaxis |
| Clinical Study Identifier | NCT05149365 |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Last Modified on | 24 March 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer